KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Retained Earnings: 2017-2024

Historic Retained Earnings for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to -$607.1 million.

  • Amneal Pharmaceuticals' Retained Earnings rose 1.02% to -$570.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.1 million, marking a year-over-year increase of 1.02%. This contributed to the annual value of -$607.1 million for FY2024, which is 23.85% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Retained Earnings stood at -$607.1 million for FY2024, which was down 23.85% from -$490.2 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Retained Earnings ranged from a high of -$276.2 million in FY2021 and a low of -$607.1 million during FY2024.
  • Over the past 3 years, Amneal Pharmaceuticals' median Retained Earnings value was -$490.2 million (recorded in 2023), while the average stood at -$501.1 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Retained Earnings increased by 24.10% in 2020 and then tumbled by 47.06% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Retained Earnings (Yearly) stood at -$286.8 million in 2020, then climbed by 3.70% to -$276.2 million in 2021, then plummeted by 47.06% to -$406.2 million in 2022, then dropped by 20.68% to -$490.2 million in 2023, then decreased by 23.85% to -$607.1 million in 2024.